{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T07:38:13Z","timestamp":1768635493574,"version":"3.49.0"},"reference-count":39,"publisher":"Impact Journals, LLC","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,6,13]]},"DOI":"10.18632\/oncotarget.16314","type":"journal-article","created":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T14:54:36Z","timestamp":1489762476000},"page":"38717-38730","source":"Crossref","is-referenced-by-count":19,"title":["Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells"],"prefix":"10.18632","volume":"8","author":[{"given":"Masanobu","family":"Tsubaki","sequence":"first","affiliation":[{"name":"Division of Pharmacotherapy, Kindai University School of Pharmacy, Kowakae, Higashi-Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Takeda","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy, Kindai University School of Pharmacy, Kowakae, Higashi-Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Kino","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy, Kindai University School of Pharmacy, Kowakae, Higashi-Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuko","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Genome Biology, Kindai University School of Medicine, Osakasayama, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuki","family":"Itoh","sequence":"additional","affiliation":[{"name":"Department of Food Science and Nutrition, Kindai University School of Agriculture, Nara, Nara, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motohiro","family":"Imano","sequence":"additional","affiliation":[{"name":"Department of Surgery, Kindai University School of Medicine, Osakasayama, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Division of Chemotherapy, Kindai University School of Pharmacy, Kowakae, Higashi-Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuto","family":"Nishio","sequence":"additional","affiliation":[{"name":"Department of Genome Biology, Kindai University School of Medicine, Osakasayama, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Satou","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kindai University School of Medicine, Osakasayama, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shozo","family":"Nishida","sequence":"additional","affiliation":[{"name":"Division of Pharmacotherapy, Kindai University School of Pharmacy, Kowakae, Higashi-Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,3,17]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Melo","year":"2000","journal-title":"Blood"},{"key":"2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22","volume":"36","author":"Grosveld","year":"1984","journal-title":"Cell"},{"key":"3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Barnes","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"4","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2004-04-1242","article-title":"The Jab1\/COP9 signalosome subcomplex is a downstream mediator of Bcr-Abl kinase activity and facilitates cell-cycle progression","volume":"105","author":"Yoneda-Kato","year":"2005","journal-title":"Blood"},{"key":"5","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.leu.2402889","article-title":"Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back","volume":"17","author":"Duyster","year":"2003","journal-title":"Leukemia"},{"key":"6","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","article-title":"Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia","volume":"7","author":"Griffin","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"7","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1158\/0008-5472.CAN-03-1484","article-title":"Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia","volume":"64","author":"Talpaz","year":"2004","journal-title":"Cancer Res"},{"key":"8","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/sj.leu.2404137","article-title":"The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib","volume":"20","author":"Kaeda","year":"2006","journal-title":"Leukemia"},{"key":"9","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.cancergencyto.2004.09.021","article-title":"BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib","volume":"159","author":"Schlegelberger","year":"2005","journal-title":"Cancer Genet Cytogenet"},{"key":"10","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.leukres.2009.03.033","article-title":"ZD6474 inhibits Src kinase leading to apoptosis of imatinib-resistant K562 cells","volume":"33","author":"Huang","year":"2009","journal-title":"Leuk Res"},{"key":"11","first-page":"5761","article-title":"Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin","volume":"62","author":"Bhalla","year":"2002","journal-title":"Cancer Res"},{"key":"12","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/blood-2007-08-109330","article-title":"Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells","volume":"111","author":"Donato","year":"2008","journal-title":"Blood"},{"key":"13","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Pirmohamed","year":"2004","journal-title":"Blood"},{"key":"14","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Melo","year":"2000","journal-title":"Blood"},{"key":"15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1756-8722-4-6","article-title":"BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance","volume":"4","author":"Drexler","year":"2011","journal-title":"J Hematol Oncol"},{"key":"16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/leu.2013.184","article-title":"Multifaceted roles of GSK-3 and Wnt\/\u03b2-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention","volume":"28","author":"Cervello","year":"2014","journal-title":"Leukemia"},{"key":"17","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrclinonc.2012.71","article-title":"MET: a promising anticancer therapeutic target","volume":"9","author":"Adjei","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"18","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd4281","article-title":"Targeting RAS-ERK signalling in cancer: promises and challenges","volume":"13","author":"Poulikakos","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4143\/crt.2014.46.3.209","article-title":"Regulation and Role of EZH2 in Cancer","volume":"46","author":"Hung","year":"2014","journal-title":"Cancer Res Treat"},{"key":"20","doi-asserted-by":"crossref","first-page":"11445","DOI":"10.1073\/pnas.94.21.11445","article-title":"Activating mutations for the met tyrosine kinase receptor in human cancer","volume":"94","author":"Vande Woude","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"21","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol"},{"key":"22","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Sawyers","year":"2001","journal-title":"Science"},{"key":"23","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Cross","year":"2011","journal-title":"Blood"},{"key":"24","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Kornblau","year":"2014","journal-title":"Cancer Cell"},{"key":"25","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1158\/2159-8290.CD-12-0558","article-title":"Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer","volume":"3","author":"Galimi","year":"2013","journal-title":"Cancer Discov"},{"key":"26","doi-asserted-by":"crossref","first-page":"252ra121","DOI":"10.1126\/scitranslmed.3009073","article-title":"A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia","volume":"6","author":"Li","year":"2014","journal-title":"Sci Transl Med"},{"key":"27","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ccr.2011.11.004","article-title":"Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia","volume":"20","author":"Marais","year":"2011","journal-title":"Cancer Cell"},{"key":"28","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1158\/1535-7163.MCT-09-0408","article-title":"Basal c-Jun NH2-terminal protein kinase activity is essential for survival and proliferation of T-cell acute lymphoblastic leukemia cells","volume":"8","author":"Zhang","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"29","doi-asserted-by":"crossref","first-page":"e6124","DOI":"10.1371\/journal.pone.0006124","article-title":"ERK2, but not ERK1, mediates acquired and \u201cde novo\u201d resistance to imatinib mesylate: implication for CML therapy","volume":"4","author":"Pandiella","year":"2009","journal-title":"PLoS One"},{"key":"30","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1038\/cdd.2011.23","article-title":"Abl interconnects oncogenic Met and p53 core pathways in cancer cells","volume":"18","author":"Maina","year":"2011","journal-title":"Cell Death Differ"},{"key":"31","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1089\/ars.2014.6096","article-title":"The implication of cancer progenitor cells and the role of epigenetics in the development of novel therapeutic strategies for chronic myeloid leukemia","volume":"22","author":"Karagiannis","year":"2015","journal-title":"Antioxid Redox Signal"},{"key":"32","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1182\/blood.V95.11.3498","article-title":"Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR\/ABL-transformed hematopoietic cell lines","volume":"95","author":"Griffin","year":"2000","journal-title":"Blood"},{"key":"33","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Talpaz","year":"2003","journal-title":"Blood"},{"key":"34","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1158\/1535-7163.MCT-09-0168","article-title":"Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors","volume":"8","author":"Auberger","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"35","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.leukres.2013.06.014","article-title":"XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells","volume":"37","author":"Maia","year":"2013","journal-title":"Leuk Res"},{"key":"36","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s11095-007-9376-3","article-title":"Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells","volume":"25","author":"Saito","year":"2008","journal-title":"Pharm Res"},{"key":"37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.canlet.2009.11.017","article-title":"p21(Cip1) confers resistance to imatinib in human chronic myeloid leukemia cells","volume":"292","author":"Leon","year":"2010","journal-title":"Cancer Lett"},{"key":"38","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1186\/1471-2407-14-866","article-title":"Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia","volume":"14","author":"Abdelhay","year":"2014","journal-title":"BMC Cancer"},{"key":"39","doi-asserted-by":"crossref","first-page":"7915","DOI":"10.1007\/s13277-015-3509-9","article-title":"Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted \u201chsa-miR-2278\u201d as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A","volume":"36","author":"Can","year":"2015","journal-title":"Tumour Biol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.16314","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T19:35:51Z","timestamp":1589139351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.16314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,17]]},"references-count":39,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2017,6,13]]}},"alternative-id":["16314","28418880"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.16314","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,17]]}}}